We congratulate Ananda’s senior non-executive director, Professor Clive Page, on the tremendous success of Nasdaq quoted Verona Pharma Pharma in achieving a $10 billion sale to Merck .  Professor Page was the founder and first Chairman of Verona. Click here to read the

Worth noting that Professor Page was the founder and first Chairman of Verona Pharma which was bought recently for $10bn . He is now a Non-Exec for @AnandaPlc Melissa Sturgess. #LTH gonna do well IMO 👍

Great announcement from Ananda Pharma Plc. First patient receives dose for MRX1. Also love how Melissa Sturgess and the team use the investment hub. A small video summarising the RNS. That how you engage with investors and get people on your website! 🔥 investors.anandapharma.co.uk/announcements/…

We were absolutely thrilled to talk to Alex Ralph at The Times and The Sunday Times about our mission to combat endometriosis and other chronic pain conditions through the development of CBD-based therapies.  thetimes.com/article/6c0182…

GW Pharma proved the model. We’re building on it with a broader target set: endometriosis, neuropathy, and more. Clinical trials beginning in 2025. Learn more below. #Biotech #CBD #Ananda Melissa Sturgess

We've just called our 2025 Annual General Meeting. For all the information on this event click the link below. investors.anandapharma.co.uk/announcements/… #ana

Have to admit great comms coming out of Ananda Pharma Plc. No question to small for Melissa Sturgess to answer. investegate.co.uk/announcement/r…

actionbutton.nationbuilder.com/share/SPK-QERE…

Bordeaux, here we come! 🇫🇷 We are excited to attend Science in the City International Sept 11–12. We’ll be speaking at the Intercontinental Reception on the 11th - sharing our insights on CBD innovation. Please reach out if you plan to attend! #AnandaPharma Melissa Sturgess

We’re pleased to confirm all resolutions were passed at our 2025 AGM today. Earlier this month, CEO Melissa Sturgess shared key updates in a live Q&A on InvestorHub. Watch the recording here: investors.anandapharma.co.uk/webinars/WPGNw…

Ananda CEO Melissa Sturgess will speak at the 8th Cannabinoid Drug Dev Summit (Oct 15–16, Boston) on “Advancing Botanical CBD Drugs: Insights from Endometriosis Trials.” Will you be there? 👉ter.li/2i659b #AnandaPharma

See you later today at Science in the City! Ananda will be represented by the Chairman, Charles Morgan and CEO Melissa Sturgess. Melissa will be the guest speaker at the pre-conference Welcome Reception from 16:00–19:00!

New Spotlight: Prof. @horne_research and the The University of Edinburgh Team Joined by Croatian researchers, they are creating one of the largest endometriosis research bioresources ever assembled, combining patient data, tracking, and biological samples. Learn more: eumetriosis.eu

Inside SGS Deeside with finance director Jeremy Sturgess-Smith 🏭. GMP processes, world class kit, and a first look at MRX1. Full video on our InvestorHub via the link in our bio. #AnandaPharma #GMP #Manufacturing #MRX1 #CBD Melissa Sturgess

Well this happened faster than we expected. Trump says CBD to be reimbursed in the US, doctors trained and FDA will need an “approvable” formulation. Which is our MRX1. ✔️✔️ Ananda Pharma Plc

Hockey is so damn back, baby!

We’re featured in MJBizDaily: “How a woman-led biotech firm is advancing cannabis medicine.” CEO Melissa Sturgess will be at MJBizCon this December ahead of that, read about how pharma-grade cannabinoid research can change women’s health. Read more: mjbizdaily.com/ananda-pharma/

Ananda Pharma welcomes the move as we advance MRX1 toward US Phase 2 trials. #Biotech #CBD #ClinicalResearch

Nothing new under the sun.

We’ve shared our January 2026 Shareholder Update, outlining our transition to a private company, progress across our clinical trials, and priorities for the year ahead. Join our live shareholder webinar on Wednesday 21 January at 10am to hear directly from the team and ask